- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
The NICE Wide Prioritisation Board (PB) met on 16 April 2026 to reconsider the routing for Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]. The PB concluded that it would be appropriate to reverse the TA selection decision for this topic and subsequently assess it through the relevant clinical guideline NG18.
- ID number:
- 6539
Email enquiries
If you have any queries please email Topic.Selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 April 2026 | Topic prioritisation. Dear Stakeholders, The NICE Wide Prioritisation Board (PB) met on 16 April 2026 to reconsider the routing for Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]. The PB concluded that it would be appropriate to reverse the TA selection decision for this topic and subsequently assess it through the relevant clinical guideline NG18. |
| 16 April 2026 | Prioritisation board meeting |
| 07 April 2026 | Appraisal anticipated to begin late Sept. 2026 - Note added to the project documents |
| 16 April 2025 | Referral |
| 07 February 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on how we select topics for development, please see our page about topic prioritisation